Cargando…

Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases

BACKGROUND: Differences in the increase in matrix metalloproteinase (MMP) and decrease in tissue inhibitor of metalloproteinase (TIMP) activity may contribute to the different characteristics observed clinically on decreased intraocular pressure in patients with glaucoma or ocular hypertension. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Hiroshi, Yoneda, Masahiko, Gosho, Masahiko, Kato, Tomohiro, Zako, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4784282/ https://www.ncbi.nlm.nih.gov/pubmed/26956170 http://dx.doi.org/10.1186/s12886-016-0202-8

Ejemplares similares

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients
por: Cai, Ziyan, et al.
Publicado: (2021)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
por: El Hajj Moussa, Wissam Georges, et al.
Publicado: (2018)

Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol
por: Fuwa, Masahiro, et al.
Publicado: (2019)

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in the hair cycle
por: HOU, CHUN, et al.
Publicado: (2016)

Tear biomarkers in latanoprost and bimatoprost treated eyes
por: Reddy, Shweta, et al.
Publicado: (2018)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
por: Tanaka, Komei, et al.
Publicado: (2013)

Differential Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Thioacetamide-Induced Chronic Liver Injury
por: Park, Soo Young, et al.
Publicado: (2010)

Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Inflammation and Fibrosis of Skeletal Muscles
por: Alameddine, Hala S., et al.
Publicado: (2016)

Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas
por: Iwata, Hiroji, et al.
Publicado: (1996)

Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Echinoderms: Structure and Possible Functions
por: Dolmatov, Igor Yu., et al.
Publicado: (2021)

Decreased VEGF-A and sustained PEDF expression in a human retinal pigment epithelium cell line cultured under hypothermia
por: Takeyama, Masayuki, et al.
Publicado: (2015)

Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma
por: Qiao, Zhen-kui, et al.
Publicado: (2013)

Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases Are Essential for the Inflammatory Response in Cancer Cells
por: Sun, Jun
Publicado: (2010)

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in murine β-coronavirus-induced neuroinflammation
por: Sengupta, Sourodip, et al.
Publicado: (2022)

Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Erratum: Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in Sepsis after Major Abdominal Surgery
por: Bojic, Suzana, et al.
Publicado: (2018)

Expression of Matrix Metalloproteinase-2 and -13 and Tissue Inhibitor of Metalloproteinase-4 in Varicose Veins
por: Chang, Jee Won, et al.
Publicado: (2011)

The Effect of Imiquimod on Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Malignant Melanoma Cell Invasion
por: Jung, Jin Young, et al.
Publicado: (2014)

Matrix metalloproteinase and tissue inhibitor of metalloproteinase responses to muscle damage after eccentric exercise
por: Kim, Jooyoung, et al.
Publicado: (2016)

Effect of prostaglandin analogs on matrix metalloproteinases and tissue inhibitor of metalloproteinases in eyelid muscle specimens
por: Karli, Sapir, et al.
Publicado: (2018)

Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Endometriosis Menstrual Blood
por: Madjid, Tita Husnitawati, et al.
Publicado: (2020)

Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Are Potential Biomarkers of Pulmonary and Extra-Pulmonary Tuberculosis
por: Kathamuthu, Gokul Raj, et al.
Publicado: (2020)

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study
por: Esaki, Yoshihiko, et al.
Publicado: (2016)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama, Yuko, et al.
Publicado: (2015)

Expression and Concentration of Matrix Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinases 1 in Laryngeal Squamous Cell Carcinoma
por: Matulka, Marlena, et al.
Publicado: (2019)

Plasma Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 as Prognostic Biomarkers in Critically Ill Patients
por: Duda, Izabela, et al.
Publicado: (2020)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

ROC analysis of selected matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in psoriatic patients
por: Glazewska, Edyta K., et al.
Publicado: (2018)

Urine Levels of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Children with Type 1 Diabetes Mellitus
por: Yürük Yıldırım, Zeynep, et al.
Publicado: (2019)

Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases Ratio: A Biomarker of Bone Resorption in Geriatric Osteoporosis?
por: Bektan Kanat, Bahar, et al.
Publicado: (2023)

Expression of Matrix Metalloproteinase-2, Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1, and Changes in Alveolar Septa in Patients with Chronic Obstructive Pulmonary Disease
por: Zhang, Yongxiang, et al.
Publicado: (2020)

Differential Regulation of Matrix-Metalloproteinases and Their Tissue Inhibitors in Patients with Aneurysmal Subarachnoid Hemorrhage
por: Fischer, Marlene, et al.
Publicado: (2013)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi, Matteo, et al.
Publicado: (2014)

Comparison of the Safety and Efficacy between Preserved and Preservative-Free Latanoprost and Preservative-Free Tafluprost
por: Kim, Joon Mo, et al.
Publicado: (2021)

Tissue inhibitors of metalloproteinases
por: Murphy, Gillian
Publicado: (2011)

Angiotensin II Differentially Induces Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Production and Disturbs MMP/TIMP Balance
por: Yaghooti, Hamid, et al.
Publicado: (2010)

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2009)

Impact of metronidazole and amoxicillin combination on matrix metalloproteinases-1 and tissue inhibitors of matrix metalloproteinases balance in generalized aggressive periodontitis
por: Cifcibasi, Emine, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s539gug7dpgjt8a913ij2gk5nq